Bavarian Nordic launches MRSA vaccine effort with partner Evaxion

Bavarian Nordic has agreed to partner with Evaxion Biotech to develop a vaccine against methicillin-resistant Staphylococcus aureus (MRSA). The pair will set out to create a vaccine based on Bavarian Nordic's MVA-BN vaccine platform and will utilize Evaxion's computer-based tech to discover novel antigens. According to a release, Evaxion has demonstrated "promising" preclinical results, and the MVA-BN-based candidate will be tested in further preclinical models; human testing could begin in 2019. The Technical University of Denmark will assist in the preclinical testing. More from FierceBiotechIT

Suggested Articles

Dr. Anthony Fauci will oversee most of the ongoing COVID-19 vaccine trials in the U.S., save for Pfizer's, ProPublica reports.

COVID vaccine and drug trial pauses show that the system is working as intended to verify safety and efficacy, the FDA commissioner told Bloomberg. 

COVID-19 vaccine manufacturing partner Emergent BioSolutions should be protected from financial fallout should J&J's product fail, analysts said.